In this issue of the Journal, Morton and colleagues report thelargest and most important trial of sentinel-lymph-node biopsyfor melanoma conducted to date.1 In the trial, 1269 patientswith intermediate-thickness (1.2 to 3.5 mm) melanoma were randomlyassigned to immediate sentinel-node biopsy or to observationfor clinically detectable (palpable) lymph nodes draining thesite of the melanoma. If the biopsy showed microscopical metastases,patients underwent immediate radical lymphadenectomy. In theobservation group, lymphadenectomy was performed only afterpalpable lymph nodes were detected. The trial clearly demonstratesthat sentinel-node biopsy provides important prognostic informationand identifies patients with nodal metastases . . . [Full Text of this Article]
Source Information
From the Johns Hopkins Medical Institutions, Baltimore (C.M.B.); and the National Tumor Institute, Milan (N.C.).
Related Letters:
Sentinel-Node Biopsy in Melanoma
Thomas J. M., A'Hern R. P., Grichnik J. M., Retsas S., Lipsker D., Kanzler M. H., Levitt L., Lin A., Morton D. L., Cochran A. J., Thompson J. F., Balch C. M., Cascinelli N.
Extract |
Full Text |
PDF
N Engl J Med 2007;
356:418-421, Jan 25, 2007.
Correspondence
This article has been cited by other articles:
Nowecki, Z. I., Rutkowski, P., Michej, W.
(2008). The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2-pT3). Ann. Surg. Oncol.
15: 2223-2234
[Abstract][Full Text]
Grange, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F., Michel, C., Batard, M.-L., Baury, B., Halna, J.-M., Schmutz, J. L., Delvincourt, C., Reuter, G., Dalle, S., Bernard, P., Danzon, A.
(2008). Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France. Arch Dermatol
144: 629-636
[Abstract][Full Text]
Niakosari, F., Kahn, H. J., McCready, D., Ghazarian, D., Rotstein, L. E., Marks, A., Kiss, A., From, L.
(2008). Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma. Arch Dermatol
144: 462-467
[Abstract][Full Text]
Beavis, A., Dawson, M., Doble, P., Scolyer, R. A., Bourne, R., Li, L.-X. L., Murali, R., Stretch, J. R., Lean, C. L., Uren, R. F., Thompson, J. F.
(2008). Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma-Mass Spectrometry. Ann. Surg. Oncol.
15: 934-940
[Abstract][Full Text]
Retsas, S.
(2007). Sentinel node biopsy confers no added protection to patients with melanoma. JRSM
100: 391-392
[Full Text]
Kanzler, M. H.
(2007). The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive. Arch Dermatol
143: 785-787
[Full Text]
Thomas, J. M., A'Hern, R. P., Grichnik, J. M., Retsas, S., Lipsker, D., Kanzler, M. H., Levitt, L., Lin, A., Morton, D. L., Cochran, A. J., Thompson, J. F., Balch, C. M., Cascinelli, N.
(2007). Sentinel-Node Biopsy in Melanoma. NEJM
356: 418-421
[Full Text]
Tonks, A.
(2006). What's new in the other general journals. BMJ
333: 744-745
[Full Text]
(2006). The Prognosis for Sentinel Lymph Node Biopsies. Journal Watch Dermatology
2006: 1-1
[Full Text]
Previous
